Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income

Emmaus Life Sciences, Inc.

2023-Q1 EPS reported -$0.03 revenue$3,234,000

Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.
Operating loss $6.1M vs $32,000 loss in 2020; R&D and selling expenses increased.
Net loss attributable to common $15.9M ($0.32 per share) vs net income $1.4M ($0.03) in 2020.
Cash $2.3M at Dec 31, 2021; Endari added to Florida Medicaid preferred drug list, UAE approval obtained.
Licensed IRAK4 inhibitor from Kainos for cancer; telehealth partnership with UpScript launched.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.